Inhibrx, Inc. (INBX)
After hours:
| Previous close | 34.24 |
| Open | 34.12 |
| Bid | 34.35 x 200 |
| Ask | 34.43 x 400 |
| Day's range | 34.12 - 34.51 |
| 52-week range | 14.31 - 39.79 |
| Volume | |
| Avg. volume | 536,633 |
| Market cap | 1.803B |
| Beta (5Y monthly) | 2.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.44 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.50 |
PR NewswireInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"), the Nasdaq Global Market ("Nasdaq") informed the Company that Nasdaq intends to permit the commencement of the trading of the shares of SpinCo common stock on a "when-issu
- PR Newswire
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off").
ZacksInhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
